文章：

肺腺癌与鳞状细胞癌患者接受单次分割立体定向放射治疗后生存率及失败模式的差异

Differences between Survival Rates and Patterns of Failure of Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma Who Received Single-Fraction Stereotactic Body Radiotherapy

原文发布日期：12 February 2024

DOI: 10.3390/cancers16040755

类型: Article

开放获取: 是

英文摘要：

We investigated the survival and patterns of failure in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) in early stage non-small cell lung cancer (NSCLC) treated with single-fraction stereotactic body radiation therapy (SF-SBRT) of 27–34 Gray. A single-institution retrospective review of patients with biopsy-proven early stage ADC or SCC undergoing definitive SF-SBRT between September 2008 and February 2023 was performed. The primary outcomes were overall survival (OS) and disease-free survival (DFS). The secondary outcomes included local failure (LF), nodal failure (NF), and distant failure (DF). Of 292 eligible patients 174 had adenocarcinoma and 118 had squamous cell carcinoma. There was no significant change in any outcome except distant failure. Patients with ADC were significantly more likely to experience distant failure than patients with SCC (p= 0.0081). In conclusion, while SF-SBRT produced similar LF, NF, DFS, and OS, the higher rate of distant failure in ADC patients suggests that ongoing trials of SBRT and systemic therapy combinations should report their outcomes by histology.

摘要翻译： 

本研究旨在探讨接受单次分割立体定向放射治疗（SF-SBRT，剂量27-34 Gy）的早期非小细胞肺癌（NSCLC）患者中，腺癌（ADC）与鳞状细胞癌（SCC）的生存情况及失败模式。我们对2008年9月至2023年2月期间经活检确诊为早期ADC或SCC并接受根治性SF-SBRT治疗的患者进行了单机构回顾性分析。主要研究终点为总生存期（OS）和无病生存期（DFS），次要研究终点包括局部失败（LF）、区域淋巴结失败（NF）和远处转移（DF）。在292例符合条件患者中，174例为腺癌，118例为鳞状细胞癌。除远处转移外，其余结局指标均无显著差异。腺癌患者发生远处转移的风险显著高于鳞状细胞癌患者（p=0.0081）。综上所述，虽然SF-SBRT在局部控制、区域控制、无病生存和总生存方面疗效相近，但腺癌患者较高的远处转移率提示，当前关于SBRT联合全身治疗的临床试验应根据组织学亚型分别报告治疗结局。

原文链接：

Differences between Survival Rates and Patterns of Failure of Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma Who Received Single-Fraction Stereotactic Body Radiotherapy